Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.28 +0.32 (+1.19%)
Official Closing Price Updated: 6:30 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Here's Why Pfizer Stock Is Still a Buy ↗
Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting. 
Via The Motley Fool
Topics Intellectual Property
News headline image
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? ↗
Johnson & Johnson is a picture of stability. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗
All three can provide you with solid, consistent income. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property World Trade
News headline image
Should You Buy Guardant Health Before Feb. 19? ↗
This genomics stock appears to be at an inflection point. 
Via The Motley Fool
Topics Earnings
Pfizer Inc (NYSE:PFE) Emerges as a High-Quality Technical Breakout Candidate ↗
Via Chartmill
TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
Via Stocktwits
News headline image
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? ↗
The business may not be as strong as its performance this year suggests. 
Via The Motley Fool
News headline image
3 High-Yield Stocks to Buy Hand Over Fist in January ↗
If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close. 
Via The Motley Fool
Topics Economy
News headline image
This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years ↗
After a years-long revenue drought, there's a light at the end of the tunnel. 
Via The Motley Fool
News headline image
Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility
As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial... 
Via TokenRing AI
Topics Artificial Intelligence Economy
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
Looking for the most active stocks in the S&P500 index on Tuesday? ↗
Via Chartmill
News headline image
The Analyst Verdict: Pfizer In The Eyes Of 7 Experts ↗
 
Via Benzinga
News headline image
2 Biotech Stocks Set to Rebound in 2026 ↗
They could perhaps see sustained runs beyond this year. 
Via The Motley Fool
News headline image
Why Is Pfizer Stock Rising Tuesday? ↗
Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for the... 
Via Benzinga
News headline image
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer&#39;s Drug ↗
Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model. 
Via Benzinga
News headline image
Where Will Eli Lilly Be in 10 Years? ↗
Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
What Are Wall Street Analysts' Target Price for Pfizer Stock?
Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook. 
Via Barchart.com
Topics ETFs
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Recent Report Shows That Rep. French Hill Sold Up to $365K Worth of Pfizer Stock ↗
 
Via Benzinga
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
The Best Stocks to Invest $40 in to Start the New Year Off Right ↗
Both could reward patient investors down the line. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
AGG vs. VCIT: The Same Tiny Fee, Completely Different Holdings ↗
Explore how portfolio breadth and risk profiles set these two leading bond ETFs apart for income-focused investors. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
Pfizer CEO Calls RFK&#39;s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research ↗
Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness. 
Via Benzinga
News headline image
The HSR Paradox: How 'Early Termination' is Reshaping the 2026 M&A Landscape
A year after the most radical transformation of U.S. antitrust filing rules in nearly half a century, the domestic merger and acquisition (M&A) market is finally finding its rhythm. The Federal Trade... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Top Stock to Buy With $30 for 2026 ↗
It's a great opportunity to "buy low." 
Via The Motley Fool
Topics Intellectual Property
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of... 
Via Finterra
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.